Status:
ACTIVE_NOT_RECRUITING
Infant Mortality Reduction by the Mass Administration of Azithromycin
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Helen Keller International
Centre de Recherche en Sante de Nouna, Burkina Faso
Conditions:
Child Mortality
Eligibility:
All Genders
1-11 years
Phase:
PHASE4
Brief Summary
This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door...
Detailed Description
The MORDOR clinical trial funded by the Bill \& Melinda Gates Foundation in Malawi, Tanzania, and Niger demonstrated that biannual oral azithromycin distributions to children aged 1-59 months signific...
Eligibility Criteria
Inclusion
- Community eligibility criteria:
- Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins
- Verbal consent of the community leader is obtained
- Inclusion criteria for children:
- Aged 1 to 11 months
- Living in one of the communities participating in the study
Exclusion
- Community exclusion criteria:
- • Inaccessible or unsafe for the study team
- Exclusion criteria for children:
- • Known allergy to macrolides
Key Trial Info
Start Date :
October 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
694400 Patients enrolled
Trial Details
Trial ID
NCT04716712
Start Date
October 4 2021
End Date
January 30 2026
Last Update
March 13 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94158
2
Centre de Recherche en Sante de Nouna
Nouna, Burkina Faso
3
Helen Keller International
Ouagadougou, Burkina Faso